Abstract:In the proposed intelligent biosensing drug‐induced cardiotoxicity assessment platform, the cardiomyocytes are treated with non‐cardiotoxic or cardiotoxic drugs to obtain mechanical beating signals. The beating signals are converted into image representations by phase space reconstruction and analyzed by convolutional neural network to identify the cardiotoxicity of drugs. Drug‐induced cardiotoxicity often leads to patient deaths and drug recalls. Interdigitated electrode (IDE)‐based cellular impedance detection instrument has been integrated with intelligent algorithms to screen cardiotoxicity based on cardiomyocytes. These intelligent biosensing systems generally employ traditional machine learning methods to assess drug‐induced cardiotoxicity by analyzing cardiomyocytes mechanical beating signals. However, modern deep learning methods with robustness and flexibility have not been integrated in IDE‐based platform to screen cardiotoxicity. Here, for the first time, we implemented deep convolutional neural network (CNN) to analyze cardiomyocytes mechanical beating signals for cardiotoxicity assessment. This method can eliminate the feature engineering procedures, such as manual design and extraction of signal features required by traditional machine learning methods. To facilitate two‐dimensional (2‐D) CNN analysis, we utilized phase space reconstruction to convert one‐dimensional beating signals into 2‐D image representations as well as take into account nonlinear dynamic information. The phase space reconstruction‐assisted convolutional neural network (PSRCNN) is capable of accurately categorizing drug‐induced cardiotoxicities and predicting cardiotoxicity levels. It obtains accuracies ranging from 0.82 to 0.99 when recognizing the cardiotoxicity of newly developed drugs, which are represented by drugs that are not used during model training. Furthermore, we explore in depth to compare the performance of CNN with other traditional machine learning methods. The PSRCNN method can achieve higher accuracies when compared to other methods. The PSRCNN‐based biosensing platform is highly potential in improving the efficiency and accuracy of high‐throughput screening of newly developed drugs for cardiotoxicity during drug discovery.

Evolution Profile for Assessing Drug-Induced Arrhythmia Using Multifunctional Cardiomyocyte-Based Biosensor

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Beating Cardiac Cell-Based Biosensor and Its Application in Drugs Screening

A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating.

High-temporal-range Drug-Induced Cardiac Side-Effect Evaluation Using Simultaneous HL-1-based Impedance and Long-Term Electrophysiology Recording Systems

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Cardiac Cell-based Biosensor and Its Biomedical Applications

A Biosensing System Using a Multiparameter Nonlinear Dynamic Analysis of Cardiomyocyte Beating for Drug-Induced Arrhythmia Recognition

Multifunctional Cardiomyocyte-Based Biosensor For Electrophysiology-Mechanical Beating-Growth Viability Monitoring

Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity

Integrated Cell-Based Biosensor for Extracellular Electrophysiological Monitoring

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

Universal and Sensitive Drug Assessment Biosensing Platform Using Optimal Mechanical Beating Detection of Single Cardiomyocyte

Electromechanical Integrated Recording of Single Cardiomyocyte in Situ by Multimodal Microelectrode Biosensing System.

High-Throughput Assessment Of Drug Cardiac Safety Using A High-Speed Impedance Detection Technology-Based Heart-On-A-Chip

Drug evaluations using a novel microphysiometer based on cell-based biosensors

Synchronized High-Content Recording of Cardiomyocytes in Vitro by Integrated Cell-Based Biosensor

Recognition of High-Specificity Herg K+ Channel Inhibitor-Induced Arrhythmia in Cardiomyocytes by Automated Template Matching

High-Throughput Drug Screening System Based on Human Induced Pluripotent Stem Cell-Derived Atrial Myocytes ∼ A Novel Platform to Detect Cardiac Toxicity for Atrial Arrhythmias

Advances in Multidimensional Cardiac Biosensing Technologies: From Electrophysiology to Mechanical Motion and Contractile Force

An intelligent biosensing platform using phase space reconstruction‐assisted convolutional neural network for drug‐induced cardiotoxicity assessment